Amarin Corporation plc Sponsored ADR logo

Amarin Corporation plc Sponsored ADR (AMRN)

Market Closed
17 Jul, 20:00
NASDAQ (CM) NASDAQ (CM)
$
13. 94
-0.24
-1.6925%
$
297.21M Market Cap
- P/E Ratio
- Div Yield
43,200 Volume
- Eps
$ 14.18
Previous Close
Analysts:
Add Transaction
Day Range
13.94 14.43
Year Range
12.96 20.9
Want to track AMRN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Amarin (AMRN) Surges 12.5%: Is This an Indication of Further Gains?

Amarin (AMRN) Surges 12.5%: Is This an Indication of Further Gains?

Amarin (AMRN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks | 9 months ago
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?

Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?

Here is how Amarin (AMRN) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

Zacks | 11 months ago
Amarin (AMRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Amarin (AMRN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for Amarin (AMRN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks | 11 months ago
Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?

Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?

Here is how Amarin (AMRN) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.

Zacks | 11 months ago
Amarin Corporation plc (AMRN) Q2 2025 Earnings Call Transcript

Amarin Corporation plc (AMRN) Q2 2025 Earnings Call Transcript

Amarin Corporation plc (NASDAQ:AMRN ) Q2 2025 Earnings Conference Call July 30, 2025 8:00 AM ET Company Participants Aaron D. Berg - CEO, President & Director Mark Marmur - Corporate Participant Peter L.

Seekingalpha | 11 months ago
Amarin Gears Up to Report Q2 Earnings: Here's What to Expect

Amarin Gears Up to Report Q2 Earnings: Here's What to Expect

AMRN braces up for second-quarter results as U.S. Vascepa sales are likely to slide, while growth in the EU looks imminent.

Zacks | 11 months ago
3 Strong Buy Breakout Stocks for Explosive Returns

3 Strong Buy Breakout Stocks for Explosive Returns

MAMA, BSET and AMRN meet breakout criteria with strong earnings growth and prices near 52-week highs.

Zacks | 1 year ago
Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus

Take the Zacks Approach to Beat the Markets: Amarin, Mogo, 3M in Focus

Zacks' model upgrades drove major gains for Amarin, Mogo and 3M, even as broader markets wobbled on tariff fears.

Zacks | 1 year ago
Are Medical Stocks Lagging Amarin (AMRN) This Year?

Are Medical Stocks Lagging Amarin (AMRN) This Year?

Here is how Amarin (AMRN) and Abbott (ABT) have performed compared to their sector so far this year.

Zacks | 1 year ago
Best Momentum Stock to Buy for June 27th

Best Momentum Stock to Buy for June 27th

GTX, LPG and AMRN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 27, 2025.

Zacks | 1 year ago
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU

Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU

AMRN jumps 27% after inking an exclusive EU licensing deal with Recordati to expand Vazkepa's reach and cut costs.

Zacks | 1 year ago
Amarin (AMRN) Soars 27.3%: Is Further Upside Left in the Stock?

Amarin (AMRN) Soars 27.3%: Is Further Upside Left in the Stock?

Amarin (AMRN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks | 1 year ago
Loading...
Load More